AriBio will reassess its route to the stock market, including a standalone initial public offering, after AriBio Holdings terminated their planned merger. The company will also discuss its listing strategy with Fosun Pharma, its licensing partner and strategic investor for AR1001, an oral Alzheimer’s treatment. The review comes as AriBio prepares to disclose topline results from a global Phase 3 trial in November. AriBio aims to seek U.S. Food and Drug Administration approval next year, commercialize AR1001 in 2028 and generate 1 trillion won in revenue by 2030. AriBio Holdings said it will lead the group’s capital-market efforts, while AriBio Lab advances a Phase 2 shingles-vaccine trial toward Phase 3 development.